Oritavancin: First global approval

Drugs

Volumn 74, Issue 15, 2014, Pages 1823-1828

  Markham, Anthony ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMPICILLIN; AZITHROMYCIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DAPTOMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; ORITAVANCIN; TEICOPLANIN; VANCOMYCIN; ANTI-BACTERIAL AGENTS; GLYCOPEPTIDES;

ABSCESS; ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ARTICLE; BACTERIAL SKIN DISEASE; CELLULITIS; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; GRAM POSITIVE INFECTION; HUMAN; INJECTION SITE REACTION; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MODERATE HEPATIC IMPAIRMENT; NAUSEA; OSTEOMYELITIS; PATENT; PHLEBITIS; PLASMA CONCENTRATION-TIME CURVE; SINGLE DRUG DOSE; TACHYCARDIA; UNITED STATES; VOLUME OF DISTRIBUTION; VOMITING; CHEMISTRY; DRUG EFFECTS; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIOLOGY; SKIN DISEASES, BACTERIAL;

ANTI-BACTERIAL AGENTS; DRUG APPROVAL; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; SKIN DISEASES, BACTERIAL;

EID: 84922005267     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0295-4     Document Type: Article

References (30)

1. Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70(7):859-86.
2. The Medicines Company. FDA approves The Medicines Company's ORBACTIV(Tm) (oritavancin) for use in acute bacterial skin and skin structure infections [media release]. 2014.
3. US Food and Drug Administration. FDA approves Orbactiv to treat skin infections [media release]. Aug 6 2014. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm408475.htm.
4. The Medicines Company. ORBACTIV (oritavancin): US prescribing information. 2014. http://www.themedicinescompany.com/app/webroot/img/orbactiv-prescribing-information.pdf. Accessed 18 Aug 2014.
5. The Medicines Company. FDA grants QIDP designation to The Medicines Company's investigational antibiotic oritavancin [media release]. 11 Nov 2013. http://www.themedicinescompany.com.
6. The Medicines Company. European medicines agency accepts marketing authorization application for The Medicines Company's oritavancin [media release]. 27 Feb 2014. http://www.themedco.com.
7. The Medicines Company. The Medicines Company completes acquisition of Targanta Therapeutics Corporation [media release]. 26 Feb 2009. http://www.themedicinescompany.com.
8. The Medicines Company. The Medicines Company to acquire Targanta Therapeutics [media release]. 29 May 2009. http://www.themedicinescompany.com.
9. Targanta Therapeutics Corporation. Targanta acquires late-stage antibiotic from InterMune [media release]. 27 Dec 2005. http://www.targanta.com.
10. Eli Lilly Company, InterMune Inc. Lilly licenses oritavancin antibiotic to InterMune [media release]. 20 Sep 2001. http://www.lilly.com.
11. The Medicines Company. 2013 Annual report. 2013. http://ir.themedicinescompany.com/phoenix.zhtml?c=122204&p=irol-reportsannual. Accessed 22 August 2014.
12. Mendes RE, Farrell DJ, Sader HS, et al. Oritavancin microbiologic features and activity results from the surveillance program in the United States. Clin Infect Dis. 2012;54(SUPPL. 3):S203-13.
13. Farrell DJ, Mendes RE, Streit JM, et al. Current analysis of oritavancin potency when tested against vancomycin-resistant/susceptible enterococcal clinical isolates recovered from European medical centres (2009-2013) [abstract no. eP171]. In: 24th European Congress of Clinical Microbiology and Infectious Diseases; 10-13 May 2014; Barcelona, Spain.
14. Farrell DJ, Mendes RE, Flamm RK, et al. Activity of oritavancin and comparator agents against multidrug-resistant staphylococcal and streptococcal isolates responsible for documented infections in European hospitals (2011-2013) [abstract no. aP172]. In: 24th European Congress of Clinical Microbiology and Infectious Diseases; 10-13 May 2014; Barcelona, Spain.
15. Belley A, Arhin FF, Moeck G. Oritavancin does not antagonise the activity of common antibacterial agents for Gram-positive and Gram-negative infections [abstract no. eP174]. In: 24th European Congress of Clinical Microbiology and Infectious Diseases; 10-13 May 2014; Barcelona, Spain.
16. McKay GA, Beaulieu S, Arhin FF, et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother. 2009;63(6):1191-9.
17. Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis. 2012;54(suppl. 3):S214-9.
18. Darpo B, Lee SK, Moon TE, et al. Oritavancin, a new lipoglycopeptide antibiotic: results from a thorough QT study. J Clin Pharmacol. 2010;50(8):895-903.
19. Bellibas SE, Huang NY, Darpo B, et al. The effects of supratherapeutic dose of oritavancin on ECG intervals: a thorough QT study in health volunteers [abstract no. A-1307]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 5-9 September 2014; Washington, DC.
20. Rubino CM, Van Wart SA, Bhavnani SM, et al. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother. 2009;53:4422-8.
21. Rubino CM, Bhavnani SM, Moeck G, et al. Population pharmacokinetics (PPK) analysis for oritavancin (ORI) based on data from patients with acute bacterial skin and skin structure infectious (ABSSSI) [abstract no. A-1308]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 5-9 September 2014; Washington, DC.
22. Fetterly GJ, Ong CM, Bhavnani SM, et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother. 2005;49(1):148-52.
23. Moriarty SR, Rakhit A, Loutit J. Safety and pharmacokinetics of a single infusion of oritavancin in subjects with moderate hepatic insufficiency and in healthy controls [abstract no. A1-1289]. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12-15 September 2009; San Francisco, CA.
24. Bhavnani SM, Hammel JP, Rubino CM, et al. Oritavancin pharmacokinetic-pharmacodynamic analyses for efficacy based on data from patients with acute bacterial skin and skin structure infections enrolled in SOLO I and SOLO II [abstract and poster no. A-1309]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 5-9 September 2014; Washington, DC.
25. Corey GR, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370(23):2180-90.
26. Corey R, Perez A, Moeck G, et al. A single-dose of oritavancin (ORI) is comparable to 7-10 days of vancomycin (VAN) in the treatment of acute bacterial skin and skin structure infections (ABSSSI): the SOLO II study [abstract no. L-206c]. In: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 10-13 Sep 2013; Denver, Colorado.
27. Holland TL, Corey GR, Wikler M, et al. A single dose of oritavancin (Ori) compared to 7-10 days of vancomycin (Van) in the treatment of acute bacterial skin and skin structure infections (Absssi): an analysis of the Mrsa subpopulation in the solo non-inferiority studies [abstract]. In: Hospital Medicine 2014; 24-27 March 2014; Las Vagas, Nevada.
28. Corey GR, Wikler M, Jiang H, et al. A single dose of oritavancin (ORI) compared to 7-10 days of vancomycin (VAN): clinical response across different lesion types in the SOLO non-inferiority studies [abstract no. O152]. In: 24th European Congress of Clinical Microbiology and Infectious Diseases; 12-15 May 2014; Barcelona, Spain.
29. Bates BM, Hartman CS, Wasilewski M. Oritavancin in the treatment of complicated skin and skin structure infections (cSSSI): combind results of two phase 3 multinational trials [abstract no. L-1514]. In: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America 46th Annual Meeting; 25-28 October 2008; Washington, DC.
30. Dunbar LM, Milata J, McClure T, et al. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother. 2011;55(7):3476-84.